Comprehensive Report on the Self-Administered Parenteral Market: Opportunities and Challenges

 This report presents a fact-based view of the self-administered parenteral sector to help companies respond to market shifts and uncover growth potential.

 

 Self-Administered Parenteral Market Valuation Forecast: What Will The Market Be Worth By 2025?
 The self-administered parenteral market size has grown strongly in recent years. It will grow from $24.57 billion in 2024 to $25.84 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to rise in chronic diseases, aging population, government initiatives, patient education and support programs, the rising incidences of bone disorders.
 
 The self-administered parenteral market size is expected to see steady growth in the next few years. It will grow to $30.83 billion in 2029 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to increasing patient preference for home healthcare, telemedicine and remote patient monitoring, patient education and support initiatives, growing personalized medicine. Major trends in the forecast period include integration of digital health solutions, customized drug delivery systems, emergence of targeted therapies, advancements in biologics.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=13927&type=smp
 
 What Are The Key Factors Driving Growth In The Self-Administered Parenteral Market?
 The growing incidence of chronic diseases is expected to propel the growth of the self-administered parenteral market going forward. Chronic diseases are long-lasting medical conditions that generally progress slowly over time and often require ongoing management and treatment. Self-administered parenteral products are used in the management of chronic diseases to manage treatment independently, which can significantly improve adherence compared to oral medication. For instance, in January 2023, according to the National Institutes of Health, a US-based government agency, among the population aged 50 or above, the number of people with at least one chronic disease is expected to increase by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. Therefore, the growing incidence of chronic diseases is driving the growth of the self-administered parenteral market.
 
 Emerging And High-Growth Segments In The Global Self-Administered Parenteral Market
 The self-administered parenteralmarket covered in this report is segmented — 
 
 1) By Product: Pre-Filled Syringes; Autoinjectors; Pen Injectors; Other Products
 2) By Usage: Disposable; Reusable
 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Home Healthcare Providers; Specialty Clinics; Other Distribution Channels
 4) By Application: Cardiovascular Diseases; Diabetes; Osteoporosis; Pain Management; Hormone Replacement; Other Applications
 
 
 Subsegments:
 1) By Pre-Filled Syringes: Glass Pre-Filled Syringes; Plastic Pre-Filled Syringes
 2) By Autoinjectors: Disposable Autoinjectors; Reusable Autoinjectors
 3) By Pen Injectors: Insulin Pen Injectors; Growth Hormone Pen Injectors; Other Pen Injectors
 4) By Other Products: Infusion Pumps; Needle-Free Injectors; Combination Devices
 
 What Are The Prominent Trends In The Self-Administered Parenteral Market?
 Major companies operating in the self-administered parenteral market are focusing on developing innovative products, such as the UDENYCA autoinjector, to provide increased choice and control, ultimately making treatment more accessible to patients. An autoinjector is a medical device designed to deliver a single dose of a particular drug. It is an intuitive design with administration triggered immediately and reliably by push-on-skin activation. For instance, in May 2023, Coherus BioSciences Inc., a US-based biotech company, launched the UDENYCA autoinjector, a self-administered parenteral medication in the US. The UDENYCA Autoinjector is a single-dose, prefilled autoinjector that offers patients an additional administration option for pegfilgrastim. It is designed to be intuitive, with administration triggered by push-on-skin activation, allowing for reliable and immediate delivery of a full pegfilgrastim dose. Additionally, it offers several user-friendly features that promote successful delivery, including fast dosing, intuitive design, dual coverage, at-home and in-office use, and a reduction of febrile neutropenia risk.
 
 Key Self-Administered Parenteral Company Insights:
 Major companies operating in the self-administered parenteral market report are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Terumo Corporation, Catalent Inc., Dexcom Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Biocon Limited, Insulet Corporation, Halozyme Therapeutics Inc., Ypsomed AG, Antares Pharma Inc., SHL Medical AG, Owen Mumford Ltd., Novartis AG, Kaleo Inc., Haselmeier AG, Bespak (A Consort Medical Company), Senseonics Holdings Inc., ScPharmaceuticals Inc., Fresenius Kabi AG
 
 View the full self-administered parenteral market report here:
 https://www.thebusinessresearchcompany.com/report/self-administered-parenteral-global-market-report
 
 How Does Self-Administered Parenteral Market Growth Vary Across Major Regions?
 North America was the largest region in the self-administered parenteral market in 2024. The regions covered in the self-administered parenteral market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company